These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 17704420

  • 1. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab.
    Zhang W, Gordon M, Schultheis AM, Yang DY, Nagashima F, Azuma M, Chang HM, Borucka E, Lurje G, Sherrod AE, Iqbal S, Groshen S, Lenz HJ.
    J Clin Oncol; 2007 Aug 20; 25(24):3712-8. PubMed ID: 17704420
    [Abstract] [Full Text] [Related]

  • 2. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab.
    Zhang W, Gordon M, Press OA, Rhodes K, Vallböhmer D, Yang DY, Park D, Fazzone W, Schultheis A, Sherrod AE, Iqbal S, Groshen S, Lenz HJ.
    Pharmacogenet Genomics; 2006 Jul 20; 16(7):475-83. PubMed ID: 16788380
    [Abstract] [Full Text] [Related]

  • 3. FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.
    Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S.
    Gut; 2015 Jun 20; 64(6):921-8. PubMed ID: 25011934
    [Abstract] [Full Text] [Related]

  • 4. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.
    Musolino A, Naldi N, Bortesi B, Pezzuolo D, Capelletti M, Missale G, Laccabue D, Zerbini A, Camisa R, Bisagni G, Neri TM, Ardizzoni A.
    J Clin Oncol; 2008 Apr 10; 26(11):1789-96. PubMed ID: 18347005
    [Abstract] [Full Text] [Related]

  • 5. FCGR2A, FCGR3A polymorphisms and therapeutic efficacy of anti-EGFR monoclonal antibody in metastatic colorectal cancer.
    Ying HQ, Wang F, Chen XL, He BS, Pan YQ, Jie C, Liu X, Cao WJ, Peng HX, Lin K, Wang SK.
    Oncotarget; 2015 Sep 29; 6(29):28071-83. PubMed ID: 26363448
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer.
    Pander J, Gelderblom H, Antonini NF, Tol J, van Krieken JH, van der Straaten T, Punt CJ, Guchelaar HJ.
    Eur J Cancer; 2010 Jul 29; 46(10):1829-34. PubMed ID: 20418097
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma.
    Weng WK, Levy R.
    J Clin Oncol; 2003 Nov 01; 21(21):3940-7. PubMed ID: 12975461
    [Abstract] [Full Text] [Related]

  • 11. Fc-γ Receptor Polymorphisms, Cetuximab Therapy, and Survival in the NCIC CTG CO.17 Trial of Colorectal Cancer.
    Liu G, Tu D, Lewis M, Cheng D, Sullivan LA, Chen Z, Morgen E, Simes J, Price TJ, Tebbutt NC, Shapiro JD, Jeffery GM, Mellor JD, Mikeska T, Virk S, Shepherd LE, Jonker DJ, O'Callaghan CJ, Zalcberg JR, Karapetis CS, Dobrovic A.
    Clin Cancer Res; 2016 May 15; 22(10):2435-44. PubMed ID: 27179112
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximab.
    Kjersem JB, Skovlund E, Ikdahl T, Guren T, Kersten C, Dalsgaard AM, Yilmaz MK, Fokstuen T, Tveit KM, Kure EH.
    BMC Cancer; 2014 May 19; 14():340. PubMed ID: 24884501
    [Abstract] [Full Text] [Related]

  • 14. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
    Paez D, Paré L, Espinosa I, Salazar J, del Rio E, Barnadas A, Marcuello E, Baiget M.
    Cancer Sci; 2010 Sep 19; 101(9):2048-53. PubMed ID: 20550522
    [Abstract] [Full Text] [Related]

  • 15. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
    Shepshelovich D, Townsend AR, Espin-Garcia O, Latifovic L, O'Callaghan CJ, Jonker DJ, Tu D, Chen E, Morgen E, Price TJ, Shapiro J, Siu LL, Kubo M, Dobrovic A, Ratain MJ, Xu W, Mushiroda T, Liu G.
    Cancer Med; 2018 Nov 19; 7(11):5478-5487. PubMed ID: 30318772
    [Abstract] [Full Text] [Related]

  • 16. Pharmacogenetic profiling and cetuximab outcome in patients with advanced colorectal cancer.
    Dahan L, Norguet E, Etienne-Grimaldi MC, Formento JL, Gasmi M, Nanni I, Gaudart J, Garcia S, Ouafik L, Seitz JF, Milano G.
    BMC Cancer; 2011 Nov 25; 11():496. PubMed ID: 22117530
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab.
    Khambata-Ford S, Garrett CR, Meropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK, Tan BR, Krishnamurthi SS, Burris HA, Poplin EA, Hidalgo M, Baselga J, Clark EA, Mauro DJ.
    J Clin Oncol; 2007 Aug 01; 25(22):3230-7. PubMed ID: 17664471
    [Abstract] [Full Text] [Related]

  • 19. First-line single-agent cetuximab in elderly patients with metastatic colorectal cancer. A phase II clinical and molecular study of the Spanish group for digestive tumor therapy (TTD).
    Sastre J, Aranda E, Grávalos C, Massutí B, Varella-Garcia M, Rivera F, Soler G, Carrato A, Manzano JL, Díaz-Rubio E, Hidalgo M.
    Crit Rev Oncol Hematol; 2011 Jan 01; 77(1):78-84. PubMed ID: 20042346
    [Abstract] [Full Text] [Related]

  • 20. FCGR2A/CD32A and FCGR3A/CD16A variants and EULAR response to tumor necrosis factor-α blockers in psoriatic arthritis: a longitudinal study with 6 months of followup.
    Ramírez J, Fernández-Sueiro JL, López-Mejías R, Montilla C, Arias M, Moll C, Alsina M, Sanmarti R, Lozano F, Cañete JD.
    J Rheumatol; 2012 May 01; 39(5):1035-41. PubMed ID: 22467926
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.